Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Patent
1994-07-15
1997-07-01
Crouch, Deborah
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
424136, 514 44, 935 55, A61K 4800, F01N 6300, C12N 1500
Patent
active
056435673
ABSTRACT:
Disclosed are methods and compositions for the suppression of expression of the neu oncogene, as well as suppression of neu oncogene-mediated transformation, tumorigenesis and metastasis. The method disclosed involves introduction of adenovirus early 1A gene (the E1A gene) products, or the large T antigen (the LT gene product), or both into affected cells. These products, which are preferably introduced by transfection of the E1A gene into affected cells, serve to suppress neu gene expression as measured by a reduction of p185 expression. Furthermore, the E1A gene products surprisingly serve to suppress the oncogenic phenotype, as indicated by a reduction in cell growth, growth in soft agar, as well as tumorigenic and metastatic potential in vivo. The inventors propose that E1A gene products, LT gene products or derivatives therefrom, may ultimately be employed a treatment modalities for neu-mediated cancers, such as cancers of the female genital tract and breast. The inventors also propose methods of transfecting cells with either the E1A or the LT gene products using adenoviral vectors or liposomes.
REFERENCES:
patent: 4394448 (1983-07-01), Szoka, Jr. et al.
Douglas et al., "Modulation of transformation of primary epithelial cells by the second exon of the Ad55 E1A12S gene," Oncogene, 6:2093-2103, 1991.
Montell et al., "Complete Transformation by Adenovirus 2 Requires Both E1A Proteins," Cell, 36:951-961, 1984.
Offringa et al., "A Novel Function of the Transforming Domain of E1a: Repression of AP-1 Activity," Cell, 62:527-538, 1990.
Whyte et al., "Cellular Targets for Transformation by the Adenovirus E1A Proteins," Cell, 56:67-75, 1989.
Freedman and Shin, "Use of Nude Mice for Studies on the Tumorigenicity of Animal Cells," The Nude Mouse in Experimental and Clinical Research, 1978.
Gazit et al., "Chemo-adoptive immunotherapy of nude nice implanted with human colorectal carcinoma and melanoma cell lines," Cancer Immunology Immunotherapy, 35:135-144, 1992.
Inoue, et al., "Consideration of Simultaneous Combination Chemotherapy--Employing a Sensitivity Test in Dunn Osteosarcoma and NR Fibrosarcoma by Intra-Test Contact of Tumor Cell Suspension, and Subcutaneous Inoculation-," Jpn. Soc. Cancer Ther. 25(12):2781-2789, 1989.
Yu et al., "Transcriptional Repression of the neu Protooncogene by the Adenovirus 5 E1A Gene Products," Proc. Natl. Acad. Sci. USA, 87:4499-4503, 1990.
Teramota et al., "Serum Enzyme Immunoassay Kit for the Detection of c-erbB-2 Oncoprotein," Annual AACI Meeting, Abstract #1446, 1991j.
Zhang et al., "Amplification and Rearrangement of c-erb B Proto-Oncogenes in Cancer of Human Femal Genital Tract," Oncogene, 4:985-989, 1989.
Slamon et al., "Studies of the HER-2
eu Proto-Oncogene in Human Breast and Ovarian Cancer," Science, 244:707-712, 1989.
Steeg et al., "Altered Expression of NM23, a Gene Associated with Low Tumor Metastatic Potential, during Adenovirus 2 Ela Inhibition of Experimental Metastasis," Cancer Res., 48:6550-6554, 1988.
Smith & Ziff, "The Amino-Terminal Region of the Adenovirus Serotype 5 Ela Protein Performs Two Separate Functions when Expressed in Primary Baby Rat Kidney Cells," Mol. Cell Biol., 8(9):3882-3890, 1988.
Bargmann & Weinberg, "Increased Tyrosine Kinase Activity Associated with the Protein Encoded by the Activated neu Oncogene," Proc. Natl. Acad. Sci. USA, 85:5394-5398, 1988.
Pozzatti et al., "The E1a Gene of Adenovirus Type 2 Reduces the Metastatic Potential of ras-Transformed Rat Embryo Cells," Mol. Cell Biol., 8(7):2984-2988, 1988.
Whyte et al., "Two Regions of the Adenovirus Early Region 1A Proteins Are Required for Transformation," J. Virol., 62(1):257-265, 1988.
Egan et al., "Transformation by Oncogenes Encoding Protein Kinases Induces the Metastatic Phenotype," Science, 238:202-205, 1987.
Sassone-Corsi & Borrelli, "Promoter Trans-Activation of Protooncogenes c-fos and c-myc, but not c-Ha-ras, by Products of Adenovirus Early Region 1A," Proc. Natl. Acad. Sci. USA, 84:6430-6433, 1987.
Kraus et al., "Overexpression of the EGF Receptor-Related Proto-Oncogene erbB-2 in Human Mammary Tumor Cell Lines by Different Molecular Mechanisms," EMBO J., 6(3):605-610, 1987.
Slamon et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2
eu Oncogene," Science, 235:177-182, 1987.
Pozzatti et al., "Primary Rat Embryo Cells Transformed by One or Two Oncogenes Show Different Metastatic Potentials," Science, 232:223-227, 1986j.
Stern et al., "p185, a Product of the neu Proto-Oncogene, Is a Receptorlike Protein Associated with Tyrosine Kinase Activity," Mol. Cell Biol., 6(5):1729-1740, 1986.
Schecter et al., "The neu Gene: An erbB-Homologous Gene Distinct from and Unlinked to the Gene Encoding the EGF Receptor," Science, 229:976-978, 1985.
Brunet et al., "Concentration Dependence of Transcriptional Transactivation in Inducible E1A-Containing Human Cells," Mol. Cell. Bio., 8(11):4799-4807 (1988).
Felgner et al., "Gene Therapeutics: The Direct Delivery of Purified Genes in vivo and Their Application as Drugs, Without the Use of Retroviruses, Is Discussed," Nature, 349:351-352 (1991).
Frisch et al., "Adenovirus E1A Represses Protease Expression and Inhibits Metastasis of Human Tumor Cells," Oncogene, 5:75-83 (1990).
Harlow et al., "Monoclonal Antibodies Specific for Adenovirus Early Region 1A Proteins: Extensive Heterogeneity in Early Region 1A Products," J. of Virology, 55(3):533-546 (1985).
Hearing et al., "Sequence-Independent Autoregulation of the Adenovirus Type 5 E1A Transcription Unit," Mol. Cell. Bio., 5(11):3214-3221 (1985).
Nabel et al., "Site-Specific Gene Expression in Vivo by Direct Gene Transfer into the Arterial Wall,"0 Science, 249:1285-88 (1990).
Moran et al., "Multiple Functional Domains in the Adenovirus E1A Gene," Cell, 48:177-178 (1987).
Ruley, "Adenovirus Early Region 1A Enables Viral and Cellular Transforming Genes to Transform Primary Cells in Culture," Nature, 304:602-606 (1983).
Senear et al., "Morphological Transformation of Established Rodent Cell Lines by High-Level Expression of the Adenvirus Type 2 E1a Gene," Mol. Cell. Bio., 6(4):1253-1260 (1986).
Suen et al., Breast Cancer Research and Treatment, 14(1):Abstract 213 (1989).
Whyte et al., "Association between an Oncogene and an Anti-Oncogene; The Adenovirus E1A Proteins Bind to the Retinoblastoma Gene Product," Nature, 334:124-129 (1988).
Yu et al., "Adenovirus Type 5 E1A Gene Products Act as Transformation Suppressors of the neu Oncogene," Mol. Cell. Bio., 11(3):1745-1750 (1991).
Zhou, et al., "A Retrovirus Vector which Transduces a Functional Estrogen Receptor Gene at High Efficiency," Mol. Endocrinology, 3(7):1157-1164 (1989).
Zhau, et al., Chemical Abstracts, 114(21):205-Abstract No. 114:200732Z (1991).
Bargmann et al., "Multiple Independent Activations of the neu Oncogene by a Point Mutation Altering the Transmembrane Domain of p185," Cell, 45:649-657, 1986.
Bargmann et al., "The neu Oncogene Encodes an Epidermal Growth Factor Receptor-Related Protein," Nature, 319:226-230, 1986.
Berk and Sharp, "Structure of the Adenovirus 2 Early mRNAs," Cell, 14:695-711, 1978.
Fung et al., "Activation of the Cellular Oncogene c-erbB by LTR Insertion: Molecular Basis for Induction of Erythroblastosis by Avian Leukosis virus," Cell, 33:357-368, 1983.
Berk, "Adenovirus Promoters and E1A Transactivation," Ann. Rev. Genet., 20:45-79, 1986.
Coussens et al., "Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene," Science, 230:1132-1139, 1985.
Downward et al., "Close Similarity of Epidermal Growth Factor Receptor and v-erb-B Oncogene protein Sequence," Nature, 307:521-527, 1984.
Haley et al., "Transformation Properties of Type 5 Adenovirus Mutants that Differentially Express the E1A Gene Products," Proc. Natl. Acad. Sci. USA, 81:5734-5738, 1984.
Houweling et al., "Partial Transformation of Primary Rat Cells by the Leftmost 4.5% Fragment of Adenovirus 5 DNA," J. Virology, 105:537-550, 1980.
Hung et al., "Amplification of the Proto-neu Oncogene Facilitates Oncogenic Activation by a Single P
Hung Mien-Chie
Matin Angahin
Yu Di-Hua
Zhang Yujiao Joe
Board of Regents , The University of Texas System
Crouch Deborah
LandOfFree
Methods for the suppression of neu mediated tumors by adenoviral does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for the suppression of neu mediated tumors by adenoviral, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the suppression of neu mediated tumors by adenoviral will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-594699